Retatrutide vs Tirzepatide: How Eli Lilly's Next-Generation GLP-1 Compares for Weight Loss and Longevity

Tirzepatide already stunned the medical world by delivering average weight loss of over 20% in clinical trials — more than any approved obesity drug in history. Now Eli Lilly is preparing to go further, with retatrutide showing even more dramatic results in early-phase trials. The question isn't just which drug is more powerful. It's whether these compounds are quietly becoming some of the most significant longevity tools ever developed.

TL;DR / Quick Summary

• Retatrutide is a triple agonist (GLP-1, GIP, glucagon receptors), while tirzepatide is a dual agonist (GLP-1, GIP) — retatrutide targets an additional metabolic pathway that accelerates fat burning.
• In Phase 2 trials, retatrutide produced average weight loss of up to 24.2% body weight over 48 weeks — surpassing tirzepatide's landmark results [1].
• Tirzepatide (Mounjaro/Zepbound) is FDA-approved; retatrutide is still in Phase 3 trials as of 2025, with no approval yet.
• Both drugs show promising effects beyond weight loss — including improvements in cardiovascular markers, metabolic health, and inflammation — with potential longevity implications.
• Neither drug is a substitute for lifestyle interventions; muscle preservation during weight loss remains a critical concern with both compounds.

Quick-Reference Comparison Table

What Makes Retatrutide Different: The Triple Threat Mechanism

To understand why retatrutide is generating so much scientific excitement, you need to know what each receptor actually does.

GLP-1 (glucagon-like peptide-1) slows gastric emptying, reduces appetite, and improves insulin secretion. This is the receptor that semaglutide (Ozempic/Wegovy) targets alone, and it's already powerful.

GIP (glucose-dependent insulinotropic polypeptide) enhances insulin release in response to meals and plays a role in fat metabolism. Adding GIP to GLP-1 — which is what tirzepatide does — significantly amplifies the weight loss and glycemic control beyond what either receptor does alone [2].

Glucagon is the third target that retatrutide adds. Glucagon is typically thought of as a hormone that raises blood sugar — but at moderate, controlled receptor stimulation, it actually increases energy expenditure and drives fat breakdown in the liver, a process called hepatic lipolysis [3].

Key Insight: The glucagon receptor component in retatrutide is what separates it from everything that came before. By carefully co-agonizing glucagon alongside GLP-1 and GIP, retatrutide can boost caloric expenditure while simultaneously suppressing appetite — a metabolic combination no approved drug currently achieves.

The challenge with glucagon co-agonism historically was raising blood glucose. Eli Lilly's molecular design balances this by ensuring the GLP-1 and GIP components counteract the hyperglycemic effect of glucagon, keeping blood sugar in check while leveraging glucagon's fat-burning benefits [3].

Bottom line: Retatrutide's triple-receptor mechanism isn't just "more of the same" — it adds a genuinely distinct metabolic pathway that tirzepatide doesn't touch.

The Clinical Trial Data: How the Numbers Stack Up

Tirzepatide's SURMOUNT-1 Results

The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, enrolled 2,539 adults with obesity. Participants on the highest dose — 15 mg weekly — lost an average of 20.9% of body weight over 72 weeks [4].

To put that in context: someone weighing 250 lbs (113 kg) could expect to lose roughly 52 lbs on the top dose, with lifestyle intervention. That's a level of efficacy previously seen only with bariatric surgery.

The trial also showed significant improvements in:

• Waist circumference (average reduction of ~14 cm at highest dose)
• Systolic blood pressure (average reduction of ~6–7 mmHg)
• Fasting insulin and insulin resistance (HOMA-IR)
• Triglycerides and HDL cholesterol

Retatrutide's Phase 2 Results

Retatrutide's Phase 2 data, published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity across multiple dose groups over 48 weeks [1].

The headline number: participants on the highest dose of 12 mg weekly lost an average of 24.2% of body weight — and the weight loss curve hadn't plateaued at 48 weeks, suggesting final results could be even greater in the longer Phase 3 trials [1].

Other notable findings from the Phase 2 data:

• 58% of participants on the 12 mg dose achieved ≥25% weight loss
• 26% achieved ≥30% weight loss — a threshold previously associated only with bariatric surgery outcomes
• Significant reductions in liver fat (assessed by MRI in a subset of participants)
• Improvements in cardiometabolic markers including triglycerides, blood pressure, and waist circumference

"The magnitude of weight loss with retatrutide at 48 weeks is unprecedented for a pharmacological agent." — Jastreboff et al., New England Journal of Medicine, 2023 [1]

Bottom line: Retatrutide's Phase 2 numbers outperform tirzepatide's landmark trial results, but Phase 2 trials involve smaller sample sizes — the Phase 3 data will be the true test.

Dosing Protocols: What the Evidence Currently Supports

Tirzepatide Dosing (Approved Protocol)

The FDA-approved titration schedule for tirzepatide (Zepbound) for obesity is:

1. 2.5 mg once weekly for the first 4 weeks (initiation dose)
2. 5 mg once weekly for weeks 5–8
3. 7.5 mg once weekly for weeks 9–12
4. 10 mg once weekly for weeks 13–16
5. 12.5 mg once weekly for weeks 17–20
6. 15 mg once weekly as the maintenance dose (if tolerated)

The slow titration exists specifically to minimize gastrointestinal side effects. Many patients find a maintenance dose below 15 mg is sufficient — clinical response, not the maximum dose, should guide prescribing decisions.

Retatrutide Dosing (Investigational — Not for Clinical Use)

In the Phase 2 trial, retatrutide was studied at doses of 1 mg, 4 mg, 8 mg, and 12 mg once weekly [1]. The 4 mg starting dose was used in some arms before titrating upward. The 12 mg dose produced the greatest weight loss but also the highest rates of GI side effects — approximately 42% of participants in that group experienced nausea.

Important: Retatrutide is not FDA-approved. There is no established or validated dosing protocol for clinical use. The numbers above are from research settings only.

⚠ Warning: Retatrutide is not available by prescription in the United States as of 2025. Any compound being sold or marketed as "retatrutide" through compounding pharmacies or online sources has not been verified for safety, purity, or efficacy. Do not use unregulated sources.

Bottom line: Tirzepatide has a well-established, FDA-validated titration protocol; retatrutide dosing remains investigational and should not be self-administered outside of approved clinical trials.

Side Effect Profiles: Where They Overlap and Where They Differ

Both drugs share a similar core side effect profile, driven primarily by their GLP-1 component. Slowing gastric emptying is what produces satiety — but it also produces nausea, especially during dose escalation.

The glucagon component in retatrutide may explain the somewhat higher nausea and vomiting rates compared to tirzepatide. Glucagon receptor agonism in the GI tract can independently stimulate nausea.

Both drugs carry the class warnings applicable to GLP-1 agonists: potential risk of thyroid C-cell tumors (observed in rodents; clinical significance in humans unconfirmed), pancreatitis, and gallbladder disease. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use these drugs [5].

Bottom line: Retatrutide's higher GI side effect rates at the maximum dose are the clearest current downside relative to tirzepatide — though tolerability at lower doses appears more comparable.

The Longevity Angle: What These Drugs Could Mean Beyond Weight Loss

Weight loss alone has significant longevity implications — obesity accelerates biological aging, drives chronic inflammation, and is a major risk factor for the leading causes of death. But the conversation around GLP-1 drugs has expanded well beyond the scale.

Cardiovascular Protection

The SELECT trial, published in the New England Journal of Medicine in 2023, demonstrated that semaglutide (a GLP-1 agonist) reduced major adverse cardiovascular events by 20% in people with obesity but without diabetes — independent of weight loss alone [6]. This suggests the drug class has direct cardioprotective properties.

Tirzepatide's SURPASS-CVOT trial is ongoing; early data is expected to confirm similar or superior cardiovascular benefits given tirzepatide's greater metabolic effects.

Retatrutide's cardiovascular outcome data is not yet available, but the Phase 2 data showed favorable effects on lipid panels, blood pressure, and inflammatory markers.

Metabolic Aging and Inflammation

Chronic low-grade inflammation — sometimes called "inflammaging" — is one of the core drivers of biological aging [7]. Visceral fat (the deep abdominal fat that surrounds organs) is a primary source of pro-inflammatory cytokines including IL-6 and TNF-alpha. Both tirzepatide and retatrutide produce dramatic reductions in visceral fat, which may translate to meaningful reductions in inflammatory burden.

Dr. Peter Attia, a physician and longevity specialist, has spoken extensively about visceral adiposity as one of the most modifiable risk factors for age-related disease. He has noted in his podcast The Drive that drugs achieving 20%+ body weight reduction — particularly visceral fat reduction — could have compounding downstream effects on cardiovascular disease risk, metabolic dysfunction, and overall lifespan trajectory.

Liver and Kidney Health

Non-alcoholic fatty liver disease (NAFLD) — now reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD) — affects roughly 25% of the global adult population and is closely linked to metabolic syndrome [8]. Retatrutide's glucagon component may offer particular advantages here, as glucagon receptor agonism is known to reduce hepatic fat through direct mechanisms beyond what caloric restriction alone achieves [3].

In the Phase 2 trial, retatrutide significantly reduced liver fat content in participants who underwent MRI assessment, with some participants showing near-complete resolution of hepatic steatosis [1].

What Longevity Experts Are Saying

Dr. David Sinclair, a Harvard geneticist and longevity researcher, has discussed metabolic health as a foundational pillar of longevity — noting that hyperinsulinemia, excess adiposity, and chronic inflammation are among the most powerful accelerators of biological aging. While Sinclair has not made specific public statements about retatrutide, his framing of metabolic optimization as central to extending healthspan aligns with the mechanistic benefits both drugs demonstrate.

Dr. Andrew Huberman has discussed GLP-1 agonists on his podcast, emphasizing the importance of pairing any GLP-1-based intervention with resistance training to minimize the muscle loss that can accompany rapid weight reduction.

Key Insight: Both tirzepatide and retatrutide cause loss of lean mass alongside fat mass — a well-documented phenomenon with any significant caloric deficit. Studies suggest approximately 25–39% of weight lost on GLP-1 drugs may come from lean tissue [9]. This makes resistance training and adequate protein intake (1.6–2.2g protein per kg of body weight daily) non-negotiable co-interventions from a longevity standpoint.

Bottom line: The longevity implications of these drugs extend well beyond aesthetics — reductions in visceral fat, inflammation, liver fat, and cardiovascular risk represent meaningful healthspan benefits, provided muscle mass is actively preserved.

Who Is Currently a Candidate for Each Drug

Tirzepatide (Available Now)

Tirzepatide is FDA-approved for:

• Adults with type 2 diabetes as an adjunct to diet and exercise (Mounjaro, approved May 2022)
• Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity such as hypertension, dyslipidemia, or type 2 diabetes (Zepbound, approved November 2023) [5]

Coverage remains inconsistent — many commercial insurance plans cover Mounjaro for diabetes but are slower to cover Zepbound for obesity. List price is approximately $1,000–$1,300/month, though manufacturer savings programs exist for eligible patients.

Retatrutide (Not Yet Available)

Retatrutide is in Phase 3 trials as of 2025. It is not approved, not commercially available, and should not be obtained outside of clinical trial settings. Phase 3 data is expected to read out in 2025–2026, which would support a potential FDA submission thereafter.

Eli Lilly is simultaneously running Phase 3 trials for retatrutide in obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH), the inflammatory form of fatty liver disease — reflecting confidence in its multi-system benefits.

Bottom line: If you're a candidate for pharmacological weight management today, tirzepatide is the most efficacious approved option available. Retatrutide remains a future option that warrants attention but not premature use.

Stacking These Drugs With Other Longevity Interventions

Neither tirzepatide nor retatrutide operates in a vacuum. The evidence consistently shows that lifestyle factors determine whether drug-driven weight loss translates into durable healthspan benefits.

Resistance Training Is Non-Negotiable

The SURMOUNT-1 trial participants receiving lifestyle counseling alongside tirzepatide lost more weight and maintained more muscle than those without structured exercise. Dr. Peter Attia's framework for longevity emphasizes that maintaining muscle mass through the "medicine cabinet" of progressive resistance training is arguably the most important physical intervention for aging — and this becomes even more critical when pharmacological weight loss is accelerating lean tissue breakdown.

Aim for 3–4 sessions of resistance training per week, prioritizing compound movements (squats, deadlifts, rows, pressing), especially during active weight loss phases on either drug.

Protein Intake

GLP-1 drugs suppress appetite broadly — including protein appetite. Many patients on these drugs inadvertently under-eat protein, which accelerates sarcopenia (muscle loss with aging). A target of 1.6–2.2g of protein per kilogram of body weight per day is supported by multiple sports science and geriatric nutrition guidelines [10].

Sleep and Stress Optimization

Poor sleep directly impairs the hormonal milieu that determines fat distribution and muscle maintenance — including ghrelin, cortisol, and growth hormone. Poor sleep can also blunt the full effectiveness of GLP-1-based therapies. Dr. Matthew Walker and other sleep researchers have documented the bidirectional relationship between obesity and sleep quality; GLP-1 drugs may actually improve sleep through weight-related reductions in sleep apnea, creating a positive feedback loop.

Metformin, Rapamycin, and Other Longevity Agents

Some longevity-focused physicians, including Dr. Peter Attia and practitioners following the model advocated by Dr. Craig Koniver (who specializes in performance medicine), have discussed combining metabolic agents with GLP-1 agonists. Metformin, for example, may have complementary effects on insulin sensitivity and AMPK activation [11]. However, drug-drug interactions and individual metabolic contexts mean these combinations require physician supervision and should never be self-prescribed.

Bottom line: GLP-1-based drugs amplify the benefits of smart lifestyle interventions — they don't replace them, and without resistance training and adequate protein, the longevity math gets considerably worse.

Frequently Asked Questions

Is retatrutide better than tirzepatide for weight loss?

Based on available data, retatrutide's Phase 2 results (~24.2% body weight loss) outperform tirzepatide's SURMOUNT-1 results (~20.9%). However, Phase 2 trials have smaller sample sizes and shorter durations than pivotal Phase 3 trials. A direct head-to-head comparison trial hasn't been completed. Phase 3 retatrutide data, expected in 2025–2026, will provide a clearer picture. [1][4]

Can I get retatrutide now?

No. As of 2025, retatrutide is not FDA-approved and is not commercially available. It is only accessible through Eli Lilly's ongoing Phase 3 clinical trials. Any compound marketed or sold as "retatrutide" through online pharmacies, compounding pharmacies, or peptide research vendors has not been validated for purity or safety and should be avoided.

Will I lose muscle on tirzepatide or retatrutide?

Both drugs can cause lean mass loss alongside fat loss, particularly at higher doses and with rapid weight reduction. Estimates suggest 25–39% of total weight lost on GLP-1 drugs may come from lean tissue [9]. This risk is significantly mitigated by progressive resistance training 3–4x/week and consuming at least 1.6–2.2g of protein per kilogram of body weight daily [10].

Are these drugs safe for people without diabetes or obesity?

Tirzepatide is FDA-approved for people with a BMI ≥30, or BMI ≥27 with a weight-related comorbidity — not exclusively for people with diabetes. The safety data outside these populations is limited. Using GLP-1 agonists for body composition optimization in people with healthy BMIs is off-label, poorly studied, and carries the same class-level risks (pancreatitis, gallbladder disease, thyroid tumor risk) without the established benefit-risk ratio present in obese populations. Consult a physician before considering either drug.

What happens when you stop taking these drugs?

Weight regain after discontinuation is well-documented with GLP-1 agonists. In the SURMOUNT-1 extension study, participants who stopped tirzepatide regained approximately two-thirds of their lost weight over 88 weeks post-discontinuation [12]. This suggests these may need to be chronic therapies for sustained effect — similar to how statins or antihypertensives are conceptualized — rather than time-limited interventions. This has significant implications for cost, access, and long-term safety monitoring.

What This Means For You

The emergence of retatrutide represents a genuine step change in the pharmacology of obesity and metabolic disease. If Phase 3 data holds up — and early indications are compelling — we may be entering an era where 25–30% body weight reduction is achievable pharmacologically, with meaningful effects on cardiovascular risk, liver health, and systemic inflammation that extend well into longevity territory.

For now, tirzepatide is the most powerful approved tool in this class. It has robust Phase 3 safety and efficacy data, FDA approval, growing clinical experience, and a well-characterized titration protocol. If you're a candidate, it's worth a serious conversation with your physician.

Retatrutide is not yet a clinical reality. Follow the Phase 3 data. Avoid unregulated sources. And in the meantime, build the lifestyle foundation — resistance training, protein, sleep, stress management — that will determine whether these drugs become a longevity tool or merely a temporary fix.

The drugs are becoming extraordinary. The biology of aging still demands more than a weekly injection to change its trajectory. Both things can be true at once.

Medical Disclaimer

The information presented in this article is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or before beginning any new supplement, peptide, medication, exercise regimen, or therapeutic protocol.

Longevity Stack does not endorse any specific tests, products, procedures, or opinions referenced in our content. Reliance on any information provided in this article is solely at your own risk. Statements made about supplements, peptides, or compounds have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.

Sources

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. https://www.nejm.org/doi/10.1056/NEJMoa2301972
2. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385(6):503-515. https://www.nejm.org/doi/10.1056/NEJMoa2107519
3. Day JW, Gelfanov V, Smiley D, et al. Optimization of co-agonism at GLP-1 and glucagon receptors to simultaneously achieve antiobesity/antidiabetic efficacy and bone loss prevention. ACS Chemical Biology. 2012;7(10):1577-1584. https://pubmed.ncbi.nlm.nih.gov/22839733/
4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. https://www.nejm.org/doi/10.1056/NEJMoa2206038
5. U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management. FDA News Release, November 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
6. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389(24):2221-2232. https://www.nejm.org/doi/10.1056/NEJMoa2307563
7. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nature Reviews Endocrinology. 2018;14(10):576-590. https://www.nature.com/articles/s41574-018-0059-4
8. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology & Hepatology. 2018;15(1):11-20. https://www.nature.com/articles/nrgastro.2017.109
9. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
10. Morton RW, Murphy KT, McKellar SR, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. British Journal of Sports Medicine. 2018;52(6):376-384. https://bjsm.bmj.com/content/52/6/376
11. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metabolism. 2014;20(6):953-966. https://www.cell.com/cell-metabolism/fulltext/S1550-4131(14)00497-8
12. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. https://jamanetwork.com/journals/jama/fullarticle/2812936